$170 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 7 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AVIR | New | ATEA PHARMACEUTICALS INC | $110,265,000 | – | 2,639,178 | +100.0% | 64.92% | – |
LUNG | New | PULMONX CORP | $57,517,000 | – | 833,333 | +100.0% | 33.86% | – |
GNCA | New | GENOCEA BIOSCIENCES INC | $908,000 | – | 375,000 | +100.0% | 0.54% | – |
SYBX | New | SYNLOGIC INC | $445,000 | – | 205,906 | +100.0% | 0.26% | – |
ARPO | New | AERPIO PHARMACEUTICALS INC | $392,000 | – | 400,000 | +100.0% | 0.23% | – |
IDRA | New | IDERA PHARMACEUTICALS INC | $206,000 | – | 56,250 | +100.0% | 0.12% | – |
New | NABRIVA THERAPEUTICS PLC | $111,000 | – | 45,849 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SYNLOGIC INC | 12 | Q3 2023 | 33.8% |
AADI BIOSCIENCES INC | 9 | Q3 2023 | 37.2% |
IDERA PHARMACEUTICALS INC | 9 | Q4 2022 | 2.4% |
GENOCEA BIOSCIENCES INC | 8 | Q3 2022 | 32.1% |
NABRIVA THERAPEUTICS PLC | 7 | Q2 2022 | 2.3% |
CASTLE BIOSCIENCES INC | 6 | Q3 2023 | 77.2% |
PULMONX CORP | 5 | Q4 2021 | 33.9% |
AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 2.3% |
ATEA PHARMACEUTICALS INC | 2 | Q2 2021 | 91.0% |
ATEA PHARMACEUTICALS INC | 1 | Q1 2021 | 80.1% |
View ABG Innovation Capital Partners III GP Ltd's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
View ABG Innovation Capital Partners III GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.